Prognostic significance of multimarker circulating tumor cell analysis in patients with advanced pancreatic cancer.

Albuquerque, Andreia; Kubisch, Ilja; Ernst, Dominikus; Breier, Georg; Kaul, S.; Fersis, N.

doi:10.1200/jco.2011.29.15_suppl.e14657

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One pitfall of PCR-based approaches is that the origin of the nucleic acids is not clear and the results may not represent actual CTCs as the nucleic acids could also include shedding from necrotic cells in tumor deposits, tumor-derived exosomes, cellular fragments or result from lysis of CTCs in the bloodstream. This limitation could be overcome by preforming an initial purification of nucleated cells from the circulation followed by extraction of nucleic acids from the cells prior to performing RT-PCR [30]. …”

Section: Isolation and Characterization Of Ctcsmentioning

confidence: 99%

Circulating tumor cells in the diagnosis and management of pancreatic cancer

Cen¹,

Yang³

et al. 2012

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

View full text Add to dashboard Cite

Pancreatic cancers are typically resistant to chemo and radiation therapy and are predisposed to distant metastases. Circulating tumor cells (CTCs) are tumor cells disseminated from primary and metastatic sites and can be isolated from peripheral blood. CTC may overcome the limitation of the current available tumor markers, CA19-9. As a surrogate for ‘real-time biopsy’, CTCs allow recurrent assessment of a tumor’s biological activity. We review the current methodologies for CTCs extraction and characterization including antibody-based immunological assays, PCR-based assays, and novel technologies based on the physical or biological characteristics of CTCs. CTCs also provide an accessible link to the existence of epithelial to mesenchymal transition, tumor stem cell markers, and ongoing clonal mutations and epigenetic changes in the tumor. We also explore the potential of using CTC profiling in diagnosis, selection of neoadjuvant and adjuvant therapy, detection of recurrent disease, examination of pharmacodynamic biomarkers, as well as in gene therapy and immunotherapy for pancreatic cancer. Ongoing CTC characterization not only has the potential to represent all cells shed from primary pancreatic tumor and each metastatic site, but also allows dynamic sampling at multiple time points during the clinical course to identify the subpopulations of CTCs and the specific molecules driving metastasis and chemo resistance. We predict that CTC genotyping and phenotyping will play an increasing role in personalized therapy and in identification of novel therapeutic targets as well as monitoring the course and status of the disease.

show abstract

Section: Isolation and Characterization Of Ctcsmentioning

confidence: 99%